Current and Future Drug Development for Cervical Cancer

This document is a technical report that presents an analysis of clinical and biological data related to drug development for cervical cancer. It outlines the current treatment modalities, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The report details ongoing clinical development programs, identifying 117 FDA-track interventional programs, with 18 in Phase 1, 80 in Phase 2, and 19 in Phase 3. Additionally, it documents the approval history of cervical cancer drugs, highlighting that only two drugs, Tivdak and Keytruda, have received FDA approval in the past five years. The report explains the prevalence of cervical cancer, particularly in low- and middle-income countries, and discusses the role of HPV vaccination in prevention. It concludes with insights into the renewed industry focus on treating cervical cancer, particularly through established targets like the PD-1/PDL-1 pathway, indicating a shift towards more treatment options in clinical development.